Wilson Disease Presenting with Catatonia
Neurol 96:e2781-e2782, Patel, R.A. & Bailey, M., 2021
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Encephalitis Induced by Immune Checkpoint Inhibitors
JAMA Neurol 78:864-873, Velasco, R.,et al, 2021
Imaging Patterns Characterizing Mitochondrial Leukodystrophies
AJNR 42:1334-1340, Roosendaal, S.D.,et al, 2021
Clinical Presentation and Management of SMART Syndrome
Neurol 97:118-120, Winter, S.F.,et al, 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Silent Myocardial Infarction and Subsequent Ischemic Stroke in the Cardiovascular Health Study
Neurol 95:e436-e443, Merkler, A.E.,et al, 2021
A 70-year-old Man with Rapid Stepwise Paraparesis and Sensory Loss
Neurol 94:e651-e655, Krause, M.A.,et al, 2020
A Rare Presentation of Whipple Disease
Neurol 94:e758-e761, Koek, A.T.,et al, 2020
Management and Outcome of Primary CNS Lymphoma in the Modern Era
Neurol 94:e1027-e1039, Houillier, C., et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Relapse of Severe Neurosarcoidosis with Switch from Originator Infliximab to Biosimilar
Neurol 94:991-993, Kidd, D.P.,et al, 2020
A 25-year-old Woman with Recurrent Episodes of Collapse and Loss of Consciousness
Neurol 94:994-999, Wildman, J.,et al, 2020
Spinal Metastases
JAMA 323:2438, Chiu, R.G.,et al, 2020
Association of Innovations in Radiotherapy and Systemic Treatments with Clinical Outcomes in Patients with Melanoma Brain Metastasis From 2007 to 2016
JAMA doi:10.1001/JAMANETWORKOPEN.2020.8204, Brastianos, H.C.,et al, 2020
Second Drug Okayed for Rare Central Nervous System Disease
JAMA 324:224, Jaklevic, M.C., 2020
Two Cases of Meningitis Associated with Ocrelizumab Therapy
Mult Scler Rel Dis 38:101866, Theriault, M. & Solomon, A.J., 2020
One-Year Sustained Efficacy of Erenumab in Episodic Migraine
Neurol 95:e469-e479, Goadsby, P.J.,et al, 2020
Steroid-Responsive Encephalitis in Coronavirus Disease 2019
Ann Neurol 88:423-427, Pilotto, A.,et al, 2020
A Young Generalized Dystonia Patient with Globus-Pallidus-Specific Lesion
Ann Neurol 88:637-638, Wu, H.,et al, 2020
Headache, Confusion, and Somnolence in a 27-Year-Old Woman
JAMA doi:10-1001/JAMA.2020.10167, Sastry, R.,et al, 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Clinicopathologic conference, Cryptococcal meningoencephalitis and advanced HIV infection
NEJM 383:2572-2580, Case 40-2020, 2020
Fat Embolism Syndrome in Sickle Cell Disease
J Clin Med 9:1-12, Tsitsikas, D.A.,et al, 2020
Diagnostic Tools for Immune Causes of Encephalitis
Clin Microbiol Infect 25:431-436, Lascano, A.M.,et al, 2019
Delayed Complications of Cranial Irradiation
www.UptoDate.com, May, Dietrich, J.,et al, 2019
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
NEJM 381:132-141, Goadsby, P.J.,et al, 2019
Cervical Synovial Cyst Leading to Spinal Cord Compression
Neurol 93:e318-e319, Urits, I.,et al, 2019
Bobblehead-Doll Syndrome
NEJM 380:e5, Sacks, C.A., 2019
Simultaneous CMV and Listeria Infection Following Alemtuzumab Treatment for Multiple Sclerosis
Neurol 92:296-298, Pappolla, A.,et al, 2019
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder
NEJM 381:614-625, Pittock, S.J.,et al, 2019
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Long-Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis
Muscle Nerve 60:14-24, Muppidi, S.,et al, 2019
Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-Blind, Randomised Placebo-Controlled Phase 2/3 Trial
Lancet 394:1352-1363,1304, Cree, B.A.C.,et al, 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Incidental Brain MRI Findings in Children:A Systematic Review and Meta-Analysis
AJNR 40:1818-1823, Dangouloff-Ros,V.,et al, 2019
GQ1b-Seronegative Miller Fisher Syndrome Associated with Pembrolizumab
J Neuro-Ophthal 39:394-396, Green, K.E.,et al, 2019
MR Imaging of the Brain in Neurologic Wilson Disease
AJNR 40:178-183, Yu, X.-E.,et al, 2019
Acute Toxic Limbic Encephalopathy Following Glyphosate Intoxication
Neurol 92:534-536, Planche, V.,et al, 2019
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy
NEJM 380:1597-1605, Cortese, I.,et al, 2019
A 23-Year-Old Man with Headaches, Confusion, and Lower Extremity Weakness
Neurol 92:863-867, Patel, N.M.,et al, 2019
Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE): Consensus Working Group Report
Brain DOI: 10.1093/brain/awz099, Nelson, P.T.,et al, 2019
Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019
Acute Viral Encephalitis
NEJM 379:357-366, Tyler,K.L., 2018
Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Distinctive Imaging in a Paucisymptomatic Child with Leukodystrophy
Neruol 91:e1368-e1369, Sharawat, I.K.,et al, 2018
Use of Newer Disease-Modifying Therapies in Pediatric Multiple Sclerosis in the US
Neurol 91:e1778-e1787, Krysko, K.M.,et al, 2018
Preventive Migraine Drug Approved
JAMA 320:1746, , 2018